CLRB | Cellectar Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2300 - 0.2495
52 Week Range	0.2200 - 4.45
Beta	0.25
Implied Volatility	155.25%
IV Rank	38.46%
Day's Volume	2,141,954
Average Volume	1,503,434
Shares Outstanding	41,269,800
Market Cap	9,698,403
Sector	Healthcare
Industry	Biotechnology
IPO Date	2005-11-10

Valuation
Profitability
Growth
Health
P/E Ratio	-0.17
Forward P/E Ratio	N/A
EPS	-1.41
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	20
Country	USA
Website	CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB's peers: AIM, CASI, DFFN, MNPR, PULM, TENX, BPTH, CBIO, CAPR, NXTC, LBPH, LUMO, IMUC, BOLT, AMTI, ALRN, BNTC, CMMB, RGLS

*Chart delayed

Analyzing fundamentals for CLRB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CLRB Fundamentals page.

Watching at CLRB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CLRB Technicals page.